fda warning letters compounded tirzepatide 2024 2025 Tirzepatide, FDA, and Compounding: Understanding the Current Landscape

Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said

24.56

★★★★☆4.8 (126)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

22.70

★★★★★4.9 (98)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

21.89

★★★★★5.0 (157)

Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines

26.32

★★★★★4.7 (84)

The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.'

25.01

★★★★★4.9 (203)

Report: FDA must enforce rules on compounded GLP-1s

23.56

★★★★★5.0 (176)

Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders

28.56

★★★★★4.8 (132)